Stock NNVC NANOVIRICIDES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NanoViricides, Inc.

Equities

NNVC

US6300873022

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:10:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.1 USD -0.90% Intraday chart for NanoViricides, Inc. 0.00% +7.84%
Feb. 14 NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Feb. 01 NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics CI

Valuation

Fiscal Period: June 2019 2021 2022 2023 2024 2025 2026
Capitalization 1 18.42 53.38 21.72 13.42 12.96 - -
Enterprise Value (EV) 1 18.42 53.38 21.72 13.42 12.96 12.96 12.96
P/E ratio -2 x -5.73 x -2.69 x -1.55 x -1.51 x -0.99 x -1.93 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - 4.32 x
EV / Revenue - - - - - - 4.32 x
EV / EBITDA - - - - - - -
EV / FCF - - - - -2.31 x -1.49 x -2.54 x
FCF Yield - - - - -43.2% -67.1% -39.4%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 3,837 11,505 11,554 11,666 11,779 - -
Reference price 2 4.800 4.640 1.880 1.150 1.100 1.100 1.100
Announcement Date 8/23/19 10/12/21 10/13/22 10/13/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 3
EBITDA - - - - - - -
EBIT 1 -8.66 - - -8.943 -8.9 -15.1 -8.8
Operating Margin - - - - - - -293.33%
Earnings before Tax (EBT) 1 -8.424 - - -8.589 -8.7 -14.8 -8.4
Net income 1 -8.424 -8.822 - -8.589 -8.7 -14.8 -8.4
Net margin - - - - - - -280%
EPS 2 -2.400 -0.8100 -0.7000 -0.7400 -0.7300 -1.110 -0.5700
Free Cash Flow 1 - - - - -5.6 -8.7 -5.1
FCF margin - - - - - - -170%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 8/23/19 10/12/21 10/13/22 10/13/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - -
EBITDA - - - - - - - - - -
EBIT 1 - -1.788 -1.793 -1.622 - - - -2.185 -2.3 -2.4
Operating Margin - - - - - - - - - -
Earnings before Tax (EBT) 1 - -1.793 -1.78 -1.571 - - - -2.115 -2.2 -2.3
Net income 1 -2.613 -1.793 -1.78 -1.571 - - -1.969 -2.115 -2.2 -2.3
Net margin - - - - - - - - - -
EPS 2 -0.2300 -0.1600 -0.1500 -0.1400 -0.1500 -0.1500 -0.1700 -0.1800 -0.1900 -0.2000
Dividend per Share - - - - - - - - - -
Announcement Date 11/15/21 5/16/22 10/13/22 11/14/22 2/14/23 5/15/23 11/14/23 2/14/24 - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2021 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - - -5.6 -8.7 -5.1
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 - - - - - -
Capex / Sales - - - - - -
Announcement Date 8/23/19 10/12/21 10/13/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.1 USD
Average target price
6.5 USD
Spread / Average Target
+490.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NANOVIRICIDES, INC. Stock NanoViricides, Inc.
+7.84% 12.96M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NNVC Stock
  4. Financials NanoViricides, Inc.